NAMS (NewAmsterdam Pharma) Future Price to Earnings

Corporate emblem and logo of NewAmsterdam Pharma N.V. (NAMS)

NewAmsterdam Pharma (NAMS) minimizes costs by outsourcing production and testing to external partners. Supply stability is guaranteed through the diversification of regional supply channels. The company is currently focused on capturing the cardiometabolic market via the launch of its flagship drug. The issuer's expected P/E helps assess the business value relative to future earnings, while 0.00 captures the current state of the parameter on the chart.

NAMS - NewAmsterdam Pharma Company Projected Price to Earnings Ratio over the range 06/21/2023 - 11/17/2026

Analytical breakdowns for NewAmsterdam Pharma

- current price and projected stock value:
General company analysis:NAMS newamsterdampharma.com
Brand item of NewAmsterdam Pharma Corp

For a comparative asset analysis, the investor utilizes this indicator as a measure of the market value of one unit of expected earnings, which allows for an assessment of the premium paid for future growth. The expected P/E multiple for NewAmsterdam Pharma (NAMS) reflects the consensus earnings forecast, which in the case of NewAmsterdam Pharma (NAMS) depends directly on the success of partnership developments in metabolic therapy and the prospects of acquisition by industry behemoths.

Competitors of NewAmsterdam Pharma (NAMS)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|MDGL (Madrigal Corp) - Future Price to Earnings Multiple|Future Price to Earnings corcept.com CORT|RYTM - Projected Price to Earnings|Akero Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Metsera Corp|MLTX (MoonLake) - Projected Price to Earnings|CRNX: Market Cap to Future Earnings Ratio|SLNO (Soleno Therapeutics Corp) - Forward P/E Multiple|Forward P/E Multiple Amicus Therapeutics|Forward P/E Multiple ETNB|Future Price to Earnings AGIO (Agios)|Future Price to Earnings structuretx.com GPCR|MiMedx Corp (MDXG) - Projected Price to Earnings Ratio|RZLT - Future Price to Earnings|LXRX: Future Price to Earnings|MBX Biosciences, Inc. (MBX) - Future Price to Earnings|ALT - Market Cap to Projected Earnings|Future Price to Earnings Aardvark Pharma|Sagimet Biosciences Inc (SGMT) - Market Cap to Projected Earnings|Future Price to Earnings bioagelabs.com (BIOA)|Projected Price to Earnings Biomea Fusion, Inc. BMEA|Future Price to Earnings Quince QNCX|GUTS (Fractyl Health Inc.) - Price to Expected Earnings Ratio|VTVT: Projected Price to Earnings|Forward Price to Earnings Multiple agapeatpgroup.com (ATPC)|PLUR (Pluri) - Projected Price to Earnings|Price to Future Earnings Ratio SYBX|Future Price to Earnings Lipocine Corporation|matinasbiopharma.com (MTNB) - Market Cap to Projected Earnings|Forward P/E Multiple SPRB|Projected Price to Earnings Galecto, Inc. GLTO|Future Price to Earnings Carmell Corporation CTCX|Future Price to Earnings Multiple LUMO|ONVO: Projected Price to Earnings|Future Price to Earnings Multiple RDUS (Radius Recycling Inc.)